Answers are grounded in this paper and cite their sources.
Vamorolone is a dissociative corticosteroid approved for the treatment of Duchenne muscular dystrophy (DMD). This review presents the clinical pharmacology program in support of its development, including dose rationale, pharmacokinetics–pharmacodynamics (PK–PD) modeling, and regulatory alignment. Key findings from early-phase studies, food effect evaluation, special population modeling, bioequivalence assessments, and comparative pharmacology evaluation are summarized. This narrative review synthesized 15 studies/investigations from peer-reviewed publications, regulatory documents, and unpublished sponsor data. Particular attention is given to the evaluation of PK in the target pediatric population across age groups, using population modeling to support individualized dosing. Vamorolone demonstrated dose-proportional PK (i.e., exposure increased in proportion to dose) in the therapeutic range, increased bioavailability with food intake, and a favorable safety profile at doses up to 6 mg/kg/day. PK–PD modeling supported individualized dosing in pediatric patients. In clinical trials and indirect treatment comparisons, vamorolone efficacy was broadly comparable to standard corticosteroids with a differentiated safety profile in which some corticosteroid-class adverse effects (notably effects on bone and growth) appeared attenuated. Clinically relevant, dose-dependent corticosteroid-class-related effects, including hypothalamic–pituitary–adrenal-axis suppression, Cushingoid features, increased weight and appetite, behavioral/mood disturbances, headache, and gastrointestinal disorders remain at therapeutic doses. The vamorolone clinical pharmacology program demonstrates how mechanistic innovation related to dissociative glucocorticoid‑receptor signaling, modeling, and strategic regulatory alignment can inform corticosteroid therapy in DMD. The differentiated mechanism of action, efficacy, individualized dosing approach, and differentiated safety profile of vamorolone make it a promising option in DMD care.
No takes yet. Share an insight, caveat, or question.
Dutreix et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: